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E-mail: jvila@ub.eduFacing the problemIn the last decade we have witnessed a dramatic increase both
in the proportion and absolute number of bacterial pathogens
presenting multidrug resistance to antibacterial agents. Orga-
nizations such as the US Centers for Disease Control and
Prevention (CDC), the European Centre for Disease Preven-
tion and Control (ECDC) and the World Health Organization
(WHO) are considering infections caused by multidrug-
resistant (MDR) bacteria as an emergent global disease and a
major public health problem.
The emergence of resistant microorganisms, either by mu-
tations or the acquisition of mobile genetic elements carrying
resistance genes, may take place irrespective of the presence of
antibacterial agents. It is the exposure to these drugs what
provides the necessary selective pressure for the rise and
spread of resistant pathogens. Therefore, the driving force
behind the increasing rates of resistance can ultimately be found
in the abuse and misuse of antibacterial agents, whether used in
patients and livestock or released into the environment. This is
no longer a medical issue. Antimicrobial resistance has become
a global health threat that will require the coordinated action of
many different stakeholders to tackle antibiotic resistance at its
very root.
The aim of the meeting organized jointly by B-Debate (Bio-
Cat) and the Barcelona Institute for Global Health (ISGlobal) in
partnership with the European Society of Clinical Microbiology
and Infectious Diseases (ESCMID) and the Spanish Network for
Research in Infectious Diseases (REIPI) was to generate debate
among the main stakeholders (i.e. policy makers, public health
authorities, regulatory agencies, pharmaceutical companies and
the scientiﬁc community at large) and come up with a coordi-
nated set of strategies to ﬁght antimicrobial resistance in a
multifaceted approach. The meeting focused on three major
areas: antimicrobial resistance in animals and the food chain; in
the environment and the community; and within the healthcare
setting. Also discussed was the lack of new therapeutic options.
Antimicrobial resistance in animals and the
food chainThe widespread use of antimicrobial agents in animals and the
food chain constitutes an important source of antimicrobialNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beha
This is an open access artiresistance, although the impact of such use on human health
remains controversial [1]. Massive amounts of antibiotics have
been used as growth promoters as well as for prophylaxis and
the treatment of infections among farm animals and in aqua-
culture, increasing the selective pressure on both commensal
and pathogenic microorganisms that can spread to humans
through direct contact and via the food chain or indirectly from
the environmental pollution of farm efﬂuents [2].
Interventions to limit the emergence and spread of resistant
bacteria in the animal setting may include the following: (a)
banning antibiotic use as growth promoters and limiting its use
for other nontherapeutic applications, (b) reducing the
dissemination of MDR bacteria through the food chain by
improving farm biosecurity and developing alternative treat-
ment strategies and increasing hygienic conditions and practices
along the food chain, (c) developing education programs, mainly
directed at veterinarians, farmers, and food handlers and (d)
linking surveillance systems on antibiotic resistance established
for humans and animals.
The European Food Safety Authority (EFSA) is playing an
essential role in detecting emerging risks in the area of MDR
bacteria within the food industry. Several proposals have been
made by EFSA for the harmonization of monitoring and
reporting of resistant bacteria, such as: (a) agreeing a
comprehensive set of antibacterial agents to be included in the
monitoring plans, (b) reinforcing antimicrobial resistance
monitoring in sentinel bacteria, (c) conducting active moni-
toring programs in healthy animals based on randomized sam-
pling plans and (d) harmonizing of epidemiological values [3].
Antibiotics that have become critical for human health
should be clearly identiﬁed and their use restricted to humans
only in order to avoid cross-resistance. In this respect, the
WHO has established a list of essential antimicrobial agents for
human use to be avoided in nonhuman interventions [4].
Compliance with the WHO recommendations, however, is
neither mandatory nor regulated. WHO has also initiated
different collaborative programs to tackle foodborne antimi-
crobial resistance through the promotion of national coordi-
nation and integrated surveillance, prevention and control of
antibiotic resistance in the food chain and the improvement of
awareness on antibiotic use and risk of resistance among vet-
erinarians and the food industry.Antimicrobial resistance within the
communityAntimicrobial resistance in the community has steadily been
increasing during the last decades, especially regarding resis-
tance to quinolones, carbapenems and third-generationlf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 6, 22–29
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of extended-spectrum β-lactamases among Enterobacteriaceae
and with the spread of high-risk clones such as Escherichia coli
ST131 [5]. Surveillance studies of antimicrobial resistance and
antibiotic consumption have drawn attention to this phenom-
enon and should be used to drive political campaigns to contain
resistance [6].
The task of the CDC/ECDC is crucial in identifying, assessing
and communicating current and emerging human health threats
on antimicrobial resistance. The latest ECDC report on antimi-
crobial resistance surveillance in Europe (http://www.ecdc.
europa.eu/en/publications/Publications/antimicrobial-resistance-
surveillance-europe-2012.pdf) showed that methicillin-resistant
Staphylococcus aureus prevalence is stabilizing or even decreasing
in some countries, while resistance to third-generation cephalo-
sporins in particular and multidrug resistance (three or four
antibacterial agents) in general continues to show a sharp and
widespread increase in E. coli and Klebsiella pneumoniae [7].
Increasing resistance to carbapenems is also becoming more
frequent in a number of countries [8].
Currently, antimicrobial consumption data from the Euro-
pean Union and countries belonging to the European Economic
Area/European Free Trade Association are expressed as a
number of deﬁned daily doses (DDD) per 1000 inhabitants and
per day. Complementary to DDD, the number of packages per
1000 inhabitants and per day are also reported, depending on
the availability of data on packages from the national surveil-
lance networks [6]. Information on packages is deemed to
improve the understanding and interpretation of differences in
the levels and trends of antimicrobial consumption observed
between and within countries, as the DDD system cannot take
into account changes in package content [9]. In addition, a drug
resistance index that aggregates information about antibiotic
resistance and antibiotic used into a single composite measure
has also been proposed [10]. Such drug resistance index, similar
to the way the Dow Jones is used in economics, would allow
the continuous quantitation of antibiotic effectiveness overtime
in particular geographic areas.
As stated above, antibiotic abuse has greatly contributed to
speed up the development of antibiotic resistance, and in this
regard human medicine has played a key role [11]. Inappro-
priate prescribing (whether caused by obsolete guidelines or
pharmaceutical pressures), over-the-counter antibiotic avail-
ability and self-medication reﬂect a general lack of awareness on
the global threat that antibiotic resistance poses to our society
[12]. Educational programs on the rational use of antibiotics
addressed to primary care physicians, drug vendors and the
community in general must be enforced to ease the pressure on
prescribers and reduce antibiotic consumption. Similarly, the
prescription of delayed receipts conditioned to the remissionNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
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such reduction.
Additional measures should include up-to-date local antibiotic
prescribing guidelines, active reporting on antibiotic prescribing
and consumption and the enforcement of local surveillance
programs on antibiotic resistance. The implementation of such
measures, however, needs substantial legislation amendments
and increased funding, which depend on a strong commitment by
policy makers at both national and international scales [13].
Of particular note is the use of antibiotics in low-income
countries, where there are additional factors contributing to
the emergence of resistance, including (a) less potent activity of
some antibacterial agents (including counterfeit drugs), (b)
over-the-counter availability, with insufﬁcient dosages, (c) lack
of diagnostic laboratories and (d) poor level of sanitation,
facilitating the familiar and community spread of resistant or-
ganisms [14,15]. Special attention should be paid to global food
commercialization and international travel.The role of the environmentThe excessive use of antimicrobial agents to treat both humans
and animals has also caused the accumulation of these com-
pounds in the environment, and the impact of such accumula-
tion on the emergence of antibiotic resistance should not be
underrated [16].
Antibacterial agents have several routes of entry into the
environment, such as sewage from the community or hospitals
through manure and water bodies [17,18]. The accumulation of
antibacterial agents further selects resistant microorganisms,
turning the environment into a gigantic reservoir for antibiotic
resistance genes that feeds on the constant and increasing envi-
ronmental pollution.Wastewater treatment plants have become
a hot spot for horizontal gene transfer and the coselection of
genetic determinants providing resistance to antibiotics, pollut-
ants, heavy metals, biocides, disinfectants, or detergents. The
current legislation on water quality mainly focuses on the pres-
ence of indicator microorganisms but does not address the
antibiotic concentrations of sewages and treatment plants.
Strategies to mitigate the risks of environmental exposure
should be aimed at improving industrial systems for sanitation
and decontamination of hospital sewage water [19].
Antimicrobial resistance within the
healthcare settingThe concurrence of high antibiotic consumption, critically ill
patients and a permanent inﬂux of pathogenic species within theEuropean Society of Clinical Microbiology and Infectious Diseases, NMNI, 6, 22–29
nses/by-nc-nd/4.0/)
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provides an ideal scenario for the dissemination of resistant
microorganisms and horizontal transfer of resistance genes.
The management of MDR microorganisms in healthcare facil-
ities is therefore a key issue.
The degree of antimicrobial resistance in these settings de-
pends on intrinsic factors related to the particular idiosyn-
crasies of each centre as well as on external factors such as the
inﬂux of resistant pathogens that originate in the community.
Intrinsic differences in resistance rates between hospitals can be
attributed to use of individual rooms vs. two or three bed-
rooms or open units, stafﬁng, antibiotic stewardship, environ-
mental cleaning, adherence to hand hygiene precautions and
infection control programs [20].
Antimicrobial consumption also shows huge interhospital
differences that might be partially explained by case mix as well
as by differences in the ﬂow of patients carrying resistance
bacteria that are transferred from other healthcare facilities
[21,22].
In order to minimize the unwanted consequences of anti-
microbial use, implementation of antimicrobial stewardship
programs should be mandatory [23,24]. Ideally, antimicrobial
stewardship should be designed to include the following: (a)
passive educational measures (antibiotic guidelines, educational
sessions), (b) active interventions (clinical rounds, prospective
audits, reassessment of antibiotic perspectives), (c) restrictive
measures (limiting antibiotics on the hospital formulary,
reporting of susceptibility by the microbiology laboratory,
antibiotic order form, preauthorization), and (d) supplemental
measures (computer-assisted management programs, multidis-
ciplinary stewardship teams, consultancy services). In addition,
infection control measures should be planned according to the
microorganisms of interest, case mix of patients and whether
endemic or epidemic [20]. Ideally, the universal screening of all
patients should be performed at admission.
Risk assessment in target pathogens needs to consider (a)
the pathogen itself, as there are different dosing strategies for
different species, (b) time of exposure—the duration of
treatment should be kept for as short as possible, (c) drug
exposure related to risk in an inverse U relationship, (d) pat-
terns of drug exposure, (e) inoculum size, with different dosing
for high-load (pneumonia) and low-load infections (surgically
treated complicated skin and soft tissue infection) and (f)
combination therapy to suppress resistance [25].Diagnosis and treatment optionsWe use breakpoints to categorize microorganisms as suscep-
tible (treatable with the agent in question) and resistant (notNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beha
This is an open access artitreatable with the agent) to guide therapy [26]. At the inter-
national level, breakpoints are ofﬁcially determined by two main
institutions: the Clinical and Laboratory Standards Institute
(CLSI) in the United States, which is a not-for-proﬁt member-
ship organization sponsored by the industry and the medical
community; and the European Committee on Antimicrobial
Susceptibility Testing (EUCAST), a joint effort among ESCMID,
ECDC, and the European Medicines Agency (EMA) [27].
Breakpoints are reviewed at regular intervals because changes
in doses, administration modes and indications for therapy
occur and new resistance mechanisms are discovered. Differ-
ences among breakpoints suggested by CLSI or EUCAST are
subtle but signiﬁcant for certain antimicrobial classes, and such
differences reﬂect the use of divergent criteria as well as
different conﬂicts of interest. In addition, there is also a
plethora of likewise national organizations providing break-
points and guidelines (i.e. BSAC, CA-SFM, CRG, DIN, NWGA,
SRGA, among others) that all together contribute to a very
poor standardization of procedures. An international harmo-
nization of breakpoints is clearly needed, and in order to ach-
ieve it, either all countries must adopt the standards of one of
the two main committees (CLSI or EUCAST), or a novel in-
ternational breakpoint committee must be created that em-
braces all of the above.
The rapid detection of resistance mechanisms plays an
important epidemiological role in surveillance studies to eval-
uate the potential dissemination of resistance genes. From the
therapeutic point of view, however, this information does not
exclude the presence of other mechanisms of resistance
affecting the same antibacterial agent. Hence, its presence has a
high predictive value for resistance but not for susceptibility. The
prompt identiﬁcation of the antimicrobial susceptibility of a
microorganism, on the other hand, ensures the administration of
the correct treatment and reduces the need for broad-spectrum
drugs, limiting the emergence of antimicrobial resistance.
Molecular methods have shortened the time to detect spe-
ciﬁc resistance mechanisms and the development of next gen-
eration sequencing technologies has increased the number of
sequenced bacterial genomes at an exponential rate. A better
understanding of the molecular basis of antimicrobial resistance
has facilitated the development of bioinformatic tools to identify
antibiotic resistance genes in bacterial genomes, such as ARG-
ANNOT, ResFinder, and the CARD database.
In addition, mass spectrometry techniques have proven
extremely useful in the rapid identiﬁcation of bacterial species
and their use in the detection of resistance proﬁles to certain
classes of antibiotics has provided excellent results [28]. Simi-
larly, advanced applications of nanoparticles and bacterial
microencapsulation to clinical are very promising and might be
fully developed in the years to come [29,30].lf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 6, 22–29
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TABLE 1. Strategies for discovery and development of novel antibacterial drugs
Strategy Description Reference
Drug derivatives Modiﬁcation of the basic structure of known antimicrobial agents or development of inhibitors of a speciﬁc
mechanism of resistance (i.e. new β-lactamases or efﬂux pump inhibitors).
[34,35]
Discovery of new antimicrobial agents Classical or whole-cell antibacterial assay to ﬁnd antibiotics produced by microorganism of different sources. [36]
Genomic or target-base antibiotic discovery with the use of new tools such as combinatorial chemistry and
genomics.
[34]
Antivirulence drugs Antibodies or compounds blocking or inhibiting virulence factors. [37]
Nanoparticles Development of antibacterial peptides or peptidomimetics. [30]
Bacteriophages or enzybiotics Delivery of bacteriophages or phage-lytic enzymes. [38,39]
Ecology/evolutionary biology approaches Aimed at targeting the ecology and evolution of antibiotic resistance, including inhibitors of plasmid transfer of
resistance, and gene-silencing antisense oligomers.
[40]
26 New Microbes and New Infections, Volume 6 Number C, --- 2015 NMNIThe development of novel therapeutic strategies, however,
seems to have reached a dead end. Despite the urgent need to
ﬁnd new antibacterial products, many pharmaceutical com-
panies have abandoned antibiotic drug discovery programs.
Several factors have contributed to this situation: (a) difﬁculty
predicting the development of resistance adding risk to
research and development (R&D) investment, (b) signiﬁcant
scientiﬁc bottlenecks, (c) complex and divergent regulatory
requirement and (d) the challenge of the commercial
model—there is high investment but low returns compared to
alternative R&D investment.
Relaunching antimicrobial drug discovery and development
should be a global priority, and some initiatives have been
suggested to encourage investment by the pharmaceutical in-
dustry, such as extending the period of exclusivity for certain
antibiotics (i.e. the GAIN (Generating Antibiotics Incentives
Now) Act) and amending regulatory requirements to accel-
erate access to antibiotics for serious infections for which there
are few, if any, alternatives.
Promoting research and development of novel antimicrobial
drugs needs to address the issue of the challenging commercial
model and come up with strategies to reconcile public health
needs with an attractive economic model for the pharmaceu-
tical industry [31]. Initiatives such as the 10 × ’20 Initiative,
promoted by the Infectious Diseases Society of America
(IDSA), that attempts to produce ten new systemic antibiotics
by the year 2020 [32], or the European Innovative Medicine
Initiative (http://www.imi.europa.eu), supporting collaborative
research projects between the pharmaceutical industry and the
academia, combine public and private funding to invigorate
antimicrobial drug research. One of these research projects to
tackle antimicrobial resistance is COMBACTE (Combatting
Bacterial Resistance in Europe), which aims to give antibiotic
drug development a much-needed boost by pioneering new
ways of designing and implementing efﬁcient clinical trials for
novel antibiotics.
Fortunately, there are also a handful of small- and medium-
size companies as well as multiple research groups that are
investing in antimicrobial drug discovery, although suchNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceinitiatives will eventually have to rely on larger corporations to
proceed through the expensive phase 2/3 of clinical
development.
In this regard, efforts are being made by EMA to relax the
regulations for clinical trials, a measure thought to cheapen and
accelerate the release of new drugs to the market.
Table 1 summarizes the different strategies that are being
used to discover and develop drugs to ﬁght bacteria.ConclusionsThe current global threat of antimicrobial resistance and the
urgent need to control it and to ﬁnd new antibacterial products
has prompted the different stakeholders to take action in inte-
grating research and public health, and in maintaining and pro-
moting the national and international antimicrobial resistance
research community. The Joint Programming Initiative on
Antimicrobial Resistance is a collaborative research initiative
supported by 18 European countries plus Canada as a response
to this threat. It has deﬁned a strategic research agenda under
the assumption that only a collaborative effort will provide the
necessary critical mass and scientiﬁc expertise to answer the
most important and urgent research questions related to anti-
microbial resistance. Other actions promoted by nonproﬁt
entities such as the World Alliance Against Antibiotic Resis-
tance (WAAAR, France), Antibiotic Action (UK), ReAct (Swe-
den) and the Antibiotic Resistance Initiative (ISGlobal, Spain),
among others, are also playing an important role in this process.
To summarize, the following measures can be taken to
prevent the emergence and spread of antibiotic resistance
worldwide: (a) rational use of antibiotics in all settings, (b)
implementation of infection control measures in healthcare
settings, (c) development of strategies to mitigate the risks of
environmental exposure, (d) development of rapid diagnostic
tests, (e) promotion of research on antibacterial resistance
prevention and surveillance, (f) promotion of research and
development of novel antimicrobial strategies and antibacterial
agents and (g) improved general awareness of antibiotic use andEuropean Society of Clinical Microbiology and Infectious Diseases, NMNI, 6, 22–29
nses/by-nc-nd/4.0/)
FIG. 1. Intervention measures to tackle antibiotic resistance. Flow of antibiotic resistance genes, antimicrobial agents and pathogens ultimately
generating multidrug-resistant bacteria and reaching a human host. Measures to prevent the emergence and dissemination of antibiotic resistance are
shown at different key points.
NMNI Roca et al. Global threat of antimicrobial resistance 27risk of increasing resistance. The ﬂow of resistance and the
main interventions that are needed to prevent the threat of
antibiotic resistance at speciﬁc key points are summarized in
Fig. 1.
The factors that have led us to the current situation and the
measures proposed to circumvent it are no novelty to the
scientiﬁc community, and much has been written about it.
Implementing those measures will demand a concerted action
of all stakeholders involved (policy makers, public health au-
thorities, regulatory agencies, pharmaceutical companies and
the scientiﬁc community at large), but above all, it will require
strong regulatory modiﬁcations and a great deal of investment.
This is the real bottleneck.
In the long run, the treatment of patients infected with drug-
resistant pathogens is much more expensive as a result of
longer hospitalization times and the use of more expensive last-
resort drugs. The annual economic burden associated with the
treatment of antibiotic-resistant infections has been estimated
to be between $21,000 and $34,000 million in the United StatesNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beha
This is an open access artialone, and around V1500 million in Europe, which includes the
economic impact associated with the number of days of lost
productivity, estimated to be approximately V450 million each
year in Europe [33].
A global and coordinated initiative to tackle antibiotic
resistance will be needed to persuade the general population
and policy makers of the advantages, both medical and eco-
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